After a rigorous selection process, we were selected to partecipate at the Merck Accelerator Program 2019, at the Merck Innovation Center in Darmstadt. The very positive feedback received by the panel of experts highlights the potential for a long-term collaboration. Beside a financial support, the program will allow our team to access Merck’s prototyping labs and network of experts and investors. This collaboration could significantly accelerate Lymphit’s entry into the market and the preclinical transition of other products in our pipeline.
Official press release on the Merck website.